Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma.

Calcified tissue international - 1 Apr 2024

Corbett Kathryn, Ruether Dean, Seiden-Long Isolde, Kline Gregory

Abstract excerpt

Ameloblastoma is a rare odontogenic tumor which may be complicated by hypercalcemia in advanced disease. Tumoral parathyroid hormone-related peptide (PTHrP) production and local osteolysis from paracrine factors have been proposed as mechanisms. Mitogen-activated protein kinase (MAPK) inhibitors have been successfully used in ameloblastomas with BRAF V600E mutation to reduce symptoms and decrease tumor burden....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ameloblastoma
Share to Calcium

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to BRAF gene

Share to Hypercalcemia

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Parathyroid Hormone-Related Protein

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38252285
DOI: 10.1007/s00223-023-01177-x

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma.PMID 38252285Read ↗

The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven TumorsSemantic proximity Read ↗

Exploiting BRAF mutations in the therapeutic approach towards oral and maxillofacial tumors.Semantic proximity Read ↗

Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up.Semantic proximity Read ↗

Precision therapy for BRAF V600E-mutated ameloblastoma: Systematic review insights.Semantic proximity Read ↗

[Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].Semantic proximity Read ↗

Cemento-osseous dysplasia is caused by RAS-MAPK activation.Semantic proximity Read ↗

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.Semantic proximity Read ↗

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.Semantic proximity Read ↗

BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.Semantic proximity Read ↗

Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.Semantic proximity Read ↗

Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.Semantic proximity Read ↗

Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.